A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS Trial)

This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.

Start Date11 Dec 2025

Sponsor / Collaborator

NewAmsterdam Pharma Corp.

NCT06982508

/ RecruitingPhase 2

A Randomized, Double-Blind, Placebo-Controlled Parallel Trial to Assess the Effects of Obicetrapib on Levels of Antioxidants in Plasma and HDL Particles in Healthy Volunteers: The VERMEER Study

The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are:
Do Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants.
Participants will:
Take Obicetrapib or a placebo every day for 4 months Visit the clinic once every 8 weeks for checkups and tests Have their blood taken and their eyes checked to measure antioxidant levels

Start Date09 Sep 2025

Sponsor / Collaborator

MB Clinical Research & Consulting LLC

NCT06496243

/ RecruitingPhase 2

A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study

The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab
Patients will:
Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16

Start Date02 Dec 2024

Sponsor / Collaborator

NewAmsterdam Pharma Co. NV

100 Clinical Results associated with Obicetrapib

100 Translational Medicine associated with Obicetrapib

100 Patents (Medical) associated with Obicetrapib

Literatures (Medical) associated with Obicetrapib

31 Dec 2025·Human Vaccines & Immunotherapeutics

Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention

Review

Author: Yang, Jiahui ; Liu, Zhengxia ; Wu, Jun ; Zhou, Ping ; Liu, Ying ; Hu, Wenhui ; Sun, Zhonghua ; Qu, Chen ; Xu, Xiaoshuang ; Feng, Han ; Tao, Xinyu

Cholesteryl ester transfer protein (CETP) plays a key role in lipoprotein metabolism, and its activity has been linked to the risk of atherosclerosis (AS). CETP inhibitors, such as obicetrapib, represent a novel approach in immunotherapy to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) by targeting lipid metabolism. In addition, CETP vaccines are being explored as a novel strategy for the prevention and treatment of ASCVD by inducing the body to produce antibodies against CETP, which is expected to reduce CETP activity, thereby increasing high-density lipoproteins (HDL) levels. This paper provides a comprehensive overview of the structure of CETP, the mechanisms of lipid transfer and the progress of immunotherapy in the last decade, which provides possible ideas for future development of novel drugs and optimization of immunization strategies.

01 Dec 2025·American journal of preventive cardiology

Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials

Article

Author: Michos, Erin D ; Araújo, Beatriz ; Queiroga, Flávia ; Amador, Wellgner Fernandes Oliveira ; Arrighini, Giang Son ; Queiroz, Ivo ; Consoli, Leo N ; Gioli-Pereira, Luciana ; Sobral, Milene Vitória Sampaio ; Akabane, Maria Antônia Costa Cruz ; Rivera, André ; Barbosa, Lucas M ; Mansouri, Ensieh Sadat

Introduction:

Obicetrapib is a novel cholesteryl ester transfer protein (CETP) inhibitor with promising lipid-lowering effects. While earlier CETP inhibitors have shown inconsistent cardiovascular outcomes and safety concerns, the efficacy and safety of obicetrapib remain under active investigation.

Methods:

We systematically searched PubMed, Embase, and Cochrane Central databases for randomized controlled trials (RCTs) comparing obicetrapib versus placebo in adults with dyslipidemia or at high cardiovascular risk. We pooled mean differences (MDs) with 95 % confidence intervals (CI) with a random effects model. We used R software version 4.4.2 for statistical analysis.

Results:

We included 7 RCTs comprising 3381 participants, of whom 2151 (63 %) received obicetrapib. The mean age was 64.3 years, and 36 % were women. Compared with placebo, obicetrapib significantly reduced mean LDL-C (MD: -37.21 %; 95 % CI: -41.53 to -32.90; p < 0.01; I²=64 %), lipoprotein(a) (MD: -37.16 %; 95 % CI: -43.63 to -30.70; p < 0.01, I²=48 %), apolipoprotein B (MD: -24.65 %; 95 % CI: -28.71 to -20.59; p < 0.01; I²=83 %), non-HDL-C (MD: -31.90 %; 95 % CI: -34.81 to -28.99; p < 0.01; I²=0 %), and triglyceride levels (MD: -7.21 %; 95 % CI: -11.13 to -3.30; p < 0.01; I²=0 %). Interestingly, obicetrapib also reduced the incidence of new-onset diabetes (RR: 0.88; 95 % CI: 0.80 to 0.97; p = 0.01; I²=0 %). In contrast, obicetrapib significantly increased HDL-C (MD: 142.17 %; 95 % CI: 117.56 to 166.78; p < 0.01; I²=98.3 %), total cholesterol (MD: 11.94 %; 95 % CI: 5.61 to 18.28; p = 0.01; I²=91 %), and apolipoprotein A1 concentrations (MD: 52.76 %; 95 % CI: 41.87 to 63.66; p < 0.01; I²=94 %). There were no significant differences in adverse events.

Conclusion:

Among patients with dyslipidemia and/or high cardiovascular risk, obicetrapib significantly reduces LDL-C, lipoprotein(a), apolipoprotein B, and non-HDL-C. No significant differences were observed in adverse events, supporting the favorable safety profile of obicetrapib.

01 Dec 2025·Alzheimers & Dementia

Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with cardiovascular disease

Article

Author: Ditmarsch, Marc ; Vijverberg, Everard G.B. ; Davidson, Michael ; Nicholls, Stephen ; Hsieh, Andrew ; Kastelein, John ; Scheltens, Philip ; Szarek, Michael ; Kling, Douglas ; Ray, Kosh K

Abstract:

Background:

Cholesteryl ester transfer protein (CETP) regulates lipid metabolism, mediating the transfer of cholesteryl esters and triglycerides between LDL and HDL cholesterol particles. The CETP inhibitor, obicetrapib, reduces LDL‐C and increases HDL‐C. Genetic evidence and preclinical studies suggest that CETP inhibition might mitigate dementia and Alzheimer’s disease (AD) risk, particularly in individuals carrying the APOE4 allele. Dysfunctional cholesterol transport is a hallmark of AD, characterized by impaired lipidation of ApoE particles leading to neuroinflammation and neurodegeneration.

Methods:

BROADWAY study (NCT05142722), a Phase 3, double‐blind, placebo‐controlled trial evaluated obicetrapib 10 mg daily versus placebo over 12 months in individuals with established atherosclerosis cardiovascular disease. Participants ( n =1727) were randomized 2:1 to treatment with obicetrapib or placebo. Plasma lipid levels including LDL‐C and HDL‐C were measured at baseline and at 12 months. AD plasma biomarkers, p ‐tau217, p ‐tau181, GFAP, NFL, and p ‐tau217/Aβ42:Aβ40 ratio, were also assessed at both time points. APOE status was determined.

Results:

The mean age of participants was 65 years, 33% were female. Obicetrapib significantly lowered LDL‐C by 33% and increased HDL‐C by 125% relative to placebo. Obicetrapib demonstrated significant attenuation of increase in the median plasma p ‐tau217 (1.1% obicetrapib vs. 4.8% with placebo; p =0.01) and p ‐tau217/Aβ42:Aβ40 ratio (2.7% obicetrapib vs. 6.5% placebo; p =0.006). At baseline, p ‐tau217 levels were higher in ApoE4 carriers compared with non‐carriers (0.47 pg/ml vs 0.39 pg/ml; ( p <0.0001). ApoE4 carriers ( n =367) showed greater benefit, with obicetrapib stabilizing p ‐tau217 levels (0% increase vs. 5.7% with placebo; p =0.03) and limiting increases in the p ‐tau217/Aβ42:Aβ40 ratio (2.1% vs. 10.2% placebo; p =0.005). Other AD biomarkers ( p ‐tau181, GFAP, NFL) showed consistent favorable trends.

Conclusions:

This very large biomarker study showed that obicetrapib significantly slowed the progression of AD biomarkers over a period of 1 year, particularly p ‐tau217 and p ‐tau217/Aβ42:Aβ40 ratio, with most pronounced effects in older individuals carrying the APOE4 allele. These findings support the dual therapeutic potential of obicetrapib in addressing both cardiovascular and neurodegenerative disorders. Given its effects on the early evolution of β‐amyloid and tau pathology, obicetrapib represents a potential advancement in the prevention of AD, particularly in ApoE4 carriers who have an increased risks for both cardiovascular and AD pathologies.

125

News (Medical) associated with Obicetrapib

04 May 2026

·www.biospace.com

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026

NAARDEN, the Netherlands and MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 50,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price per share equal to $28.43, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on May 1, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant. The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 15,400 of NewAmsterdam’s ordinary shares to five non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units were granted on May 1, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Matthew Philippe P: 1-917-882-7512 matthew.philippe@newamsterdampharma.com

Phase 3AHA

03 Apr 2026

·www.biospace.com

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 2, 2026

NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 15,000 of NewAmsterdam’s ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price per share equal to $32.81, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on April 1, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant. The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 3,200 of NewAmsterdam’s ordinary shares to two non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units were granted on April 1, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Matthew Philippe P: 1-917-882-7512 matthew.philippe@newamsterdampharma.com

Phase 3AHA

23 Mar 2026

·www.biospace.com

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the at the American College of Cardiology Annual Scientific Session (ACC.26), taking place on March 28-30 in New Orleans, Louisiana. Presentation details are as follows: Presentation Title: CETP Inhibition with Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results from the BROADWAY Trial Session Title: 1069: Next-Generation Lipid Treatment Options Digital Poster Presentation Date and Time: Saturday, March 28, 2026, 3:30 - 3:37 PM CDT Presenter: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma Location: Moderated Poster Theater 06, Posters, Hall E Presentation Title: Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis Session Title: 1084: Evolving Non-Statin Therapies Digital Poster Presentation Date and Time: Sunday, March 29, 2026, 10:18 - 10:25 AM CDT Presenter: Adam Nelson, Ph.D. Location: Moderated Poster Theater 05, Posters, Hall E Presentation Title: Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles Session Title: 1180: Linking Lipid Metrics to CVD Risks Digital Poster Presentation Date and Time: Monday, March 30, 2026, 11:00 - 11:07 AM CDT Presenter: Floriaan Schmidt, Ph.D. Location: Moderated Poster Theater 05, Posters, Hall E About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect pro to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Matthew Philippe P: 1-917-882-7512 matthew.philippe@newamsterdampharma.com Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 cedgington@realchemistry.com Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 austin.murtagh@precisionaq.com

Phase 3Clinical ResultAHA

100 Deals associated with Obicetrapib

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14890

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary hypercholesterolemia	NDA/BLA	European Union	NewAmsterdam Pharma Co. NV	18 Aug 2025
Diabetes Mellitus, Type 2	Phase 3	United States	NewAmsterdam Pharma Corp.	11 Dec 2025
Hyperlipidemias	Phase 3	United States	NewAmsterdam Pharma Corp.	11 Dec 2025
Metabolic Syndrome	Phase 3	United States	NewAmsterdam Pharma Corp.	11 Dec 2025
Hyperlipoproteinemias	Phase 3	United States	NewAmsterdam Pharma Holding BV	25 Jul 2022
Hyperlipoproteinemias	Phase 3	Canada	NewAmsterdam Pharma Holding BV	25 Jul 2022
Hyperlipoproteinemias	Phase 3	Czechia	NewAmsterdam Pharma Holding BV	25 Jul 2022
Hyperlipoproteinemias	Phase 3	Netherlands	NewAmsterdam Pharma Holding BV	25 Jul 2022
Hyperlipoproteinemias	Phase 3	Norway	NewAmsterdam Pharma Holding BV	25 Jul 2022
Hyperlipoproteinemias	Phase 3	Poland	NewAmsterdam Pharma Holding BV	25 Jul 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05425745 (BROOKLYN, Pubmed \| Nat Med)	Phase 3	Heterozygous familial hypercholesterolemia	354	Obicetrapib 10 mg	jvyjusftyu(iqvpzaisag): Difference (%) = -36.3 (95.0% CI, -42.2 to -30.4), P-Value = < 0.0001	Positive	27 Feb 2026
				Placebo
NCT06005597 (TANDEM, CTgov)	Phase 3	Atherosclerosis \| Heterozygous familial hypercholesterolemia \| Hypercholesterolemia, Familial	407	Ezetimibe Placebo (Placebo)	aqovsxdwcm(zrpsaslipi) = qoxkrzotbt oemnkttvca (kvxbhlboag, 3.564) View more	-	08 Oct 2025
				Combination Therapy placebo+Monotherapy ezetimibe (Monotherapy Ezetimibe)	gbzurujohx(zpndsitasy) = uuohjfurob ftggviutzu (krmrstnwkx, 3.497) View more
NCT05142722 (BROADWAY, Pubmed \| J Prev Alzheimers Dis)	Phase 3	Cardiovascular Diseases p-tau217 \| p-tau217/Aβ42:40 \| GFAP ... View more	1,535	Obicetrapib 10 mg	szevkhcbjm(zcjettxrwl) = itupsubgwr uwterfyixf (ueeipoebnh ) View more	Positive	01 Oct 2025
				Placebo	szevkhcbjm(zcjettxrwl) = ncpntxtvph uwterfyixf (ueeipoebnh ) View more
NCT05142722 (BROADWAY, CTgov)	Phase 3	Atherosclerosis \| Heterozygous familial hypercholesterolemia \| Hypercholesterolemia, Familial	2,530	Placebo (Placebo)	dhndivaxqs(vhbcpeuuvs) = zainuzhubn hulqwlnjma (uspldpzybl, 1.571) View more	-	19 Sep 2025
				Obicetrapib (Obicetrapib 10mg)	dhndivaxqs(vhbcpeuuvs) = jldttwkfxx hulqwlnjma (uspldpzybl, 1.104) View more
NCT05142722 \| NCT05425745 (BROADWAY, Literature) Manual	Not Applicable	Heterozygous familial hypercholesterolemia \| Atherosclerosis	2,884	Obicetrapib 10 mg	ocfvzzphhx(rdamthinwj) = azqojwomfb pmiuclcicc (rtvhuscdfh ) View more	Positive	01 Sep 2025
				Placebo	ocfvzzphhx(rdamthinwj) = zukrawdycx pmiuclcicc (rtvhuscdfh ) View more
NCT05142722 (BROADWAY, GlobeNewswire) Manual	Phase 3	Heterozygous familial hypercholesterolemia \| Atherosclerosis	1,515	Obicetrapib 10 mg	kdmfqnrycu(rjekmuhvki): Difference (%) = -20.48, P-Value = 0.010 View more	Positive	30 Jul 2025
				Placebo
NCT05142722 (BROADWAY, Pubmed \| N Engl J Med \| NEWS) Manual	Phase 3	Heterozygous familial hypercholesterolemia \| Atherosclerosis	2,530	ObicetrapibObicetrapib 10 mg	vanbykudse(scsewihogm) = aftkxpwuwe joxkrdesda (myhxeujrhh, -32.1 to -27.8)	Positive	03 Jul 2025
				Placebo	vanbykudse(scsewihogm) = retzqgkeaf joxkrdesda (myhxeujrhh, -0.4 to 5.8)
NCT05425745 (BROOKLYN, CTgov)	Phase 3	Hyperlipoproteinemias \| Heterozygous familial hypercholesterolemia	354	Placebo (Placebo)	nagdrnlesm(jdzdirmfaq) = ylmaehfflq jtxnxsmvhz (kebepqokmd, 2.480) View more	-	11 Jun 2025
				Obicetrapib (Obicetrapib 10 mg)	nagdrnlesm(jdzdirmfaq) = jpdnuvfvhd jtxnxsmvhz (kebepqokmd, 1.769) View more
NCT05142722 (BROADWAY, GlobeNewswire) Manual	Phase 3	Heterozygous familial hypercholesterolemia \| Atherosclerosis	-	Obicetrapib 10 mg	nmgimggsxc(uyidfswidk) = odjdnpaxpd lstwrrblid (mkrmkkjxrz ) View more	Positive	10 Dec 2024
				Placebo	nmgimggsxc(uyidfswidk) = lqdffuuwnj lstwrrblid (mkrmkkjxrz ) View more
NCT06005597 (TANDEM, Company_Website) Manual	Phase 3	Heterozygous familial hypercholesterolemia \| Atherosclerosis	407	Placebo	qensedkzbc(larhiqvnaj) = vkxsoxqmvf aooaxrgmwr (lmuccdqpwt ) View more	Positive	20 Nov 2024
				Ezetimibe	qensedkzbc(larhiqvnaj) = xgfqfqbjzo aooaxrgmwr (lmuccdqpwt ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis